Key facts
- This page summarizes Anthony Prentice's Form 4 filing for Sema4 Holdings Corp. (WGS).
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 13 Dec 2021, 18:05.
Anthony Prentice - 09 Dec 2021 Form 4 Insider Report for Sema4 Holdings Corp. (WGS)
- Reporting relationship
- Chief Product Officer
- Issuer ticker
- WGS
- Reported as of
- 09 Dec 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Dec 2021, 18:05:29 UTC
- Prior SEC filing
- 03 Dec 2021
- Next SEC filing
- 27 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel Clark Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Anthony Prentice filed Form 4 for Sema4 Holdings Corp. (WGS) on 13 Dec 2021.
Change
- Previous filing in this sequence was filed on 03 Dec 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
WGSWW
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +151,110
- Change %
- Price
- $0.000000
- Shares after
- 151,110
- Date
- 09 Dec 2021
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 151,110
- Exercise price
- Footnotes
- F1, F2, F3
WGSWW
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +39,211
- Change %
- Price
- $0.000000
- Shares after
- 39,211
- Date
- 09 Dec 2021
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 39,211
- Exercise price
- Footnotes
- F1, F2, F4
WGSWW
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +17,141
- Change %
- Price
- $0.000000
- Shares after
- 17,141
- Date
- 09 Dec 2021
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 17,141
- Exercise price
- Footnotes
- F1, F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration, granted pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 9, 2021 (as amended, the "Merger Agreement"), by and among CM Life Sciences, Inc., S-IV Sub, Inc. and Mount Sinai Genomics, Inc. d/b/a Sema4. In addition, in the event that any similar RSUs are forfeited (for example, as a result of the recipient no longer being an employee of the Issuer), the Merger Agreement provides for the shares underlying such forfeited RSUs to become available for issuance to other RSU recipients. Therefore, each RSU also represents to right to receive additional shares of the Issuer's Class A Common Stock from this "forfeiture pool". The number of shares of the Issuer's Class A Common Stock that may be issued to the Reporting Person pursuant to the "forfeiture pool" is not determinable at this time.
Footnote F2
[cont'd from footnote 1] Any shares of the Issuer's Class A Common Stock ultimately issued to the Reporting Person in respect of each RSU will be reported in a subsequent filing.
Footnote F3
The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date.
Footnote F4
The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date with respect to 16,452 of the RSUs, and will be satisfied with respect to the remainder of the RSUs over 8 quarterly periods, subject to the Reporting Person's continued service to the Issuer on each service-based vesting date.
Footnote F5
The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date with respect to 11,724 of the RSUs, and will be satisfied with respect to the remainder of the RSUs over 2 quarterly periods, subject to the Reporting Person's continued service to the Issuer on each service-based vesting date.